Clinical Trial

A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2

Study acronym: GAMBIT
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to measure the efficacy and safety of AZD0901 monotherapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2025-08-20; most recent amendment 2026-06-16.
Status change: Recruiting → Active, Not Recruiting 2026-03-16
Status change: Not Yet Recruiting → Recruiting 2025-09-24
Trial Details
NCT Number NCT07143604
Lead Sponsor AstraZeneca
Conditions Gastric Cancer, Gastroesophageal Junction Cancer
Enrollment 33 participants
Start Date 2025-08-29
Primary Completion 2026-09-28 (estimated)
Study Completion 2027-09-28 (estimated)
Updated on ClinicalTrials.gov 2026-06-17